nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—ovarian cancer	0.716	1	CbGaD
Gliclazide—VEGFA—myometrium—ovarian cancer	0.00291	0.113	CbGeAlD
Gliclazide—VEGFA—uterine cervix—ovarian cancer	0.00227	0.0878	CbGeAlD
Gliclazide—VEGFA—decidua—ovarian cancer	0.00216	0.0837	CbGeAlD
Gliclazide—VEGFA—endometrium—ovarian cancer	0.00205	0.0794	CbGeAlD
Gliclazide—VEGFA—uterus—ovarian cancer	0.00189	0.0732	CbGeAlD
Gliclazide—VEGFA—bone marrow—ovarian cancer	0.0016	0.0621	CbGeAlD
Gliclazide—VEGFA—female gonad—ovarian cancer	0.00154	0.0599	CbGeAlD
Gliclazide—VEGFA—vagina—ovarian cancer	0.00154	0.0595	CbGeAlD
Gliclazide—VEGFA—testis—ovarian cancer	0.00137	0.0531	CbGeAlD
Gliclazide—ABCC8—endometrium—ovarian cancer	0.00135	0.0523	CbGeAlD
Gliclazide—KCNJ11—female reproductive system—ovarian cancer	0.00121	0.0471	CbGeAlD
Gliclazide—KCNJ11—female gonad—ovarian cancer	0.0011	0.0428	CbGeAlD
Gliclazide—VEGFA—lymph node—ovarian cancer	0.000993	0.0385	CbGeAlD
Gliclazide—ABCC8—testis—ovarian cancer	0.000903	0.035	CbGeAlD
Gliclazide—KCNJ11—lymph node—ovarian cancer	0.00071	0.0275	CbGeAlD
Gliclazide—ALB—testis—ovarian cancer	0.000646	0.0251	CbGeAlD
Gliclazide—CYP2C19—vagina—ovarian cancer	0.000583	0.0226	CbGeAlD
Gliclazide—CYP2C9—female reproductive system—ovarian cancer	0.0005	0.0194	CbGeAlD
Gliclazide—ALB—lymph node—ovarian cancer	0.000469	0.0182	CbGeAlD
Gliclazide—Dermatitis—Vinorelbine—ovarian cancer	0.000129	0.000708	CcSEcCtD
Gliclazide—Abdominal distension—Doxorubicin—ovarian cancer	0.000129	0.000708	CcSEcCtD
Gliclazide—Hypotension—Paclitaxel—ovarian cancer	0.000129	0.000706	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000129	0.000706	CcSEcCtD
Gliclazide—Headache—Vinorelbine—ovarian cancer	0.000129	0.000704	CcSEcCtD
Gliclazide—Asthma—Doxorubicin—ovarian cancer	0.000128	0.000703	CcSEcCtD
Gliclazide—Leukopenia—Docetaxel—ovarian cancer	0.000128	0.000703	CcSEcCtD
Gliclazide—Palpitations—Docetaxel—ovarian cancer	0.000127	0.000694	CcSEcCtD
Gliclazide—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000127	0.000694	CcSEcCtD
Gliclazide—Weight increased—Epirubicin—ovarian cancer	0.000126	0.000692	CcSEcCtD
Gliclazide—Loss of consciousness—Docetaxel—ovarian cancer	0.000126	0.00069	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000126	0.000689	CcSEcCtD
Gliclazide—Hyperglycaemia—Epirubicin—ovarian cancer	0.000125	0.000686	CcSEcCtD
Gliclazide—Cough—Docetaxel—ovarian cancer	0.000125	0.000685	CcSEcCtD
Gliclazide—Angina pectoris—Doxorubicin—ovarian cancer	0.000125	0.000685	CcSEcCtD
Gliclazide—Insomnia—Paclitaxel—ovarian cancer	0.000125	0.000684	CcSEcCtD
Gliclazide—Pneumonia—Epirubicin—ovarian cancer	0.000124	0.000682	CcSEcCtD
Gliclazide—Convulsion—Docetaxel—ovarian cancer	0.000124	0.00068	CcSEcCtD
Gliclazide—Paraesthesia—Paclitaxel—ovarian cancer	0.000124	0.000679	CcSEcCtD
Gliclazide—Hypertension—Docetaxel—ovarian cancer	0.000124	0.000678	CcSEcCtD
Gliclazide—Drowsiness—Epirubicin—ovarian cancer	0.000124	0.000678	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—ovarian cancer	0.000123	0.000676	CcSEcCtD
Gliclazide—Dyspnoea—Paclitaxel—ovarian cancer	0.000123	0.000674	CcSEcCtD
Gliclazide—Somnolence—Paclitaxel—ovarian cancer	0.000123	0.000672	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000123	0.000672	CcSEcCtD
Gliclazide—Myalgia—Docetaxel—ovarian cancer	0.000122	0.000668	CcSEcCtD
Gliclazide—Chest pain—Docetaxel—ovarian cancer	0.000122	0.000668	CcSEcCtD
Gliclazide—Arthralgia—Docetaxel—ovarian cancer	0.000122	0.000668	CcSEcCtD
Gliclazide—Pancytopenia—Doxorubicin—ovarian cancer	0.000122	0.000668	CcSEcCtD
Gliclazide—Nausea—Vinorelbine—ovarian cancer	0.000122	0.000668	CcSEcCtD
Gliclazide—Renal failure—Epirubicin—ovarian cancer	0.000122	0.000666	CcSEcCtD
Gliclazide—Dyspepsia—Paclitaxel—ovarian cancer	0.000121	0.000666	CcSEcCtD
Gliclazide—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000121	0.000664	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000121	0.000664	CcSEcCtD
Gliclazide—Jaundice—Epirubicin—ovarian cancer	0.000121	0.000661	CcSEcCtD
Gliclazide—Conjunctivitis—Epirubicin—ovarian cancer	0.00012	0.000659	CcSEcCtD
Gliclazide—Urinary tract infection—Epirubicin—ovarian cancer	0.00012	0.000659	CcSEcCtD
Gliclazide—Dry mouth—Docetaxel—ovarian cancer	0.000119	0.000654	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000119	0.000654	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000119	0.000653	CcSEcCtD
Gliclazide—Fatigue—Paclitaxel—ovarian cancer	0.000119	0.000652	CcSEcCtD
Gliclazide—Sweating—Epirubicin—ovarian cancer	0.000119	0.00065	CcSEcCtD
Gliclazide—Pain—Paclitaxel—ovarian cancer	0.000118	0.000647	CcSEcCtD
Gliclazide—Constipation—Paclitaxel—ovarian cancer	0.000118	0.000647	CcSEcCtD
Gliclazide—Confusional state—Docetaxel—ovarian cancer	0.000118	0.000646	CcSEcCtD
Gliclazide—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000117	0.000642	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000117	0.000641	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—ovarian cancer	0.000117	0.00064	CcSEcCtD
Gliclazide—Epistaxis—Epirubicin—ovarian cancer	0.000117	0.000639	CcSEcCtD
Gliclazide—Infection—Docetaxel—ovarian cancer	0.000116	0.000637	CcSEcCtD
Gliclazide—Sinusitis—Epirubicin—ovarian cancer	0.000116	0.000636	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000116	0.000634	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—ovarian cancer	0.000115	0.000632	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—ovarian cancer	0.000115	0.000631	CcSEcCtD
Gliclazide—Nervous system disorder—Docetaxel—ovarian cancer	0.000115	0.000628	CcSEcCtD
Gliclazide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000115	0.000627	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—ovarian cancer	0.000114	0.000627	CcSEcCtD
Gliclazide—Tachycardia—Docetaxel—ovarian cancer	0.000114	0.000625	CcSEcCtD
Gliclazide—Feeling abnormal—Paclitaxel—ovarian cancer	0.000114	0.000623	CcSEcCtD
Gliclazide—Skin disorder—Docetaxel—ovarian cancer	0.000114	0.000622	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000113	0.000622	CcSEcCtD
Gliclazide—Bradycardia—Epirubicin—ovarian cancer	0.000113	0.000619	CcSEcCtD
Gliclazide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000113	0.000618	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—ovarian cancer	0.000112	0.000616	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000112	0.000615	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—ovarian cancer	0.000112	0.000611	CcSEcCtD
Gliclazide—Rhinitis—Epirubicin—ovarian cancer	0.000111	0.00061	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—ovarian cancer	0.000111	0.00061	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—ovarian cancer	0.000111	0.00061	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—ovarian cancer	0.000111	0.000608	CcSEcCtD
Gliclazide—Hypoaesthesia—Epirubicin—ovarian cancer	0.00011	0.000605	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—ovarian cancer	0.00011	0.000604	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—ovarian cancer	0.00011	0.000601	CcSEcCtD
Gliclazide—Urticaria—Paclitaxel—ovarian cancer	0.00011	0.000601	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—ovarian cancer	0.000109	0.000599	CcSEcCtD
Gliclazide—Hypotension—Docetaxel—ovarian cancer	0.000109	0.000599	CcSEcCtD
Gliclazide—Abdominal pain—Paclitaxel—ovarian cancer	0.000109	0.000598	CcSEcCtD
Gliclazide—Body temperature increased—Paclitaxel—ovarian cancer	0.000109	0.000598	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000108	0.000593	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—ovarian cancer	0.000108	0.000591	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—ovarian cancer	0.000107	0.000588	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—ovarian cancer	0.000107	0.000586	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—ovarian cancer	0.000107	0.000585	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000107	0.000584	CcSEcCtD
Gliclazide—Insomnia—Docetaxel—ovarian cancer	0.000106	0.00058	CcSEcCtD
Gliclazide—Paraesthesia—Docetaxel—ovarian cancer	0.000105	0.000575	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—ovarian cancer	0.000105	0.000575	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—ovarian cancer	0.000105	0.000573	CcSEcCtD
Gliclazide—Dyspnoea—Docetaxel—ovarian cancer	0.000104	0.000571	CcSEcCtD
Gliclazide—Somnolence—Docetaxel—ovarian cancer	0.000104	0.00057	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—ovarian cancer	0.000104	0.000569	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—ovarian cancer	0.000104	0.000567	CcSEcCtD
Gliclazide—Flushing—Epirubicin—ovarian cancer	0.000103	0.000565	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—ovarian cancer	0.000103	0.000564	CcSEcCtD
Gliclazide—Dyspepsia—Docetaxel—ovarian cancer	0.000103	0.000564	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—ovarian cancer	0.000103	0.000563	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000102	0.00056	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—ovarian cancer	0.000102	0.000559	CcSEcCtD
Gliclazide—Hypersensitivity—Paclitaxel—ovarian cancer	0.000102	0.000557	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—ovarian cancer	0.000101	0.000555	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000101	0.000553	CcSEcCtD
Gliclazide—Fatigue—Docetaxel—ovarian cancer	0.000101	0.000552	CcSEcCtD
Gliclazide—Pain—Docetaxel—ovarian cancer	0.0001	0.000548	CcSEcCtD
Gliclazide—Constipation—Docetaxel—ovarian cancer	0.0001	0.000548	CcSEcCtD
Gliclazide—Chills—Epirubicin—ovarian cancer	9.96e-05	0.000546	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—ovarian cancer	9.92e-05	0.000543	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—ovarian cancer	9.9e-05	0.000542	CcSEcCtD
Gliclazide—Asthenia—Paclitaxel—ovarian cancer	9.9e-05	0.000542	CcSEcCtD
Gliclazide—Pruritus—Paclitaxel—ovarian cancer	9.76e-05	0.000535	CcSEcCtD
Gliclazide—Mental disorder—Epirubicin—ovarian cancer	9.73e-05	0.000533	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—ovarian cancer	9.71e-05	0.000532	CcSEcCtD
Gliclazide—Erythema—Epirubicin—ovarian cancer	9.67e-05	0.00053	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—ovarian cancer	9.67e-05	0.00053	CcSEcCtD
Gliclazide—Feeling abnormal—Docetaxel—ovarian cancer	9.64e-05	0.000528	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—ovarian cancer	9.6e-05	0.000526	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—ovarian cancer	9.58e-05	0.000525	CcSEcCtD
Gliclazide—Gastrointestinal pain—Docetaxel—ovarian cancer	9.56e-05	0.000524	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—ovarian cancer	9.53e-05	0.000522	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—ovarian cancer	9.52e-05	0.000522	CcSEcCtD
Gliclazide—Tension—Epirubicin—ovarian cancer	9.48e-05	0.00052	CcSEcCtD
Gliclazide—Diarrhoea—Paclitaxel—ovarian cancer	9.44e-05	0.000517	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—ovarian cancer	9.39e-05	0.000514	CcSEcCtD
Gliclazide—Back pain—Epirubicin—ovarian cancer	9.35e-05	0.000512	CcSEcCtD
Gliclazide—Abdominal pain—Docetaxel—ovarian cancer	9.25e-05	0.000507	CcSEcCtD
Gliclazide—Body temperature increased—Docetaxel—ovarian cancer	9.25e-05	0.000507	CcSEcCtD
Gliclazide—Chills—Doxorubicin—ovarian cancer	9.22e-05	0.000505	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—ovarian cancer	9.18e-05	0.000503	CcSEcCtD
Gliclazide—Dizziness—Paclitaxel—ovarian cancer	9.12e-05	0.0005	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—ovarian cancer	9e-05	0.000493	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—ovarian cancer	8.97e-05	0.000491	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—ovarian cancer	8.94e-05	0.00049	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—ovarian cancer	8.94e-05	0.00049	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—ovarian cancer	8.93e-05	0.00049	CcSEcCtD
Gliclazide—Agitation—Epirubicin—ovarian cancer	8.88e-05	0.000487	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—ovarian cancer	8.81e-05	0.000483	CcSEcCtD
Gliclazide—Tension—Doxorubicin—ovarian cancer	8.78e-05	0.000481	CcSEcCtD
Gliclazide—Vomiting—Paclitaxel—ovarian cancer	8.77e-05	0.000481	CcSEcCtD
Gliclazide—Malaise—Epirubicin—ovarian cancer	8.72e-05	0.000478	CcSEcCtD
Gliclazide—Rash—Paclitaxel—ovarian cancer	8.7e-05	0.000477	CcSEcCtD
Gliclazide—Dermatitis—Paclitaxel—ovarian cancer	8.69e-05	0.000476	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—ovarian cancer	8.69e-05	0.000476	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—ovarian cancer	8.65e-05	0.000474	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—ovarian cancer	8.65e-05	0.000474	CcSEcCtD
Gliclazide—Headache—Paclitaxel—ovarian cancer	8.64e-05	0.000474	CcSEcCtD
Gliclazide—Hypersensitivity—Docetaxel—ovarian cancer	8.62e-05	0.000472	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—ovarian cancer	8.54e-05	0.000468	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—ovarian cancer	8.5e-05	0.000465	CcSEcCtD
Gliclazide—Cough—Epirubicin—ovarian cancer	8.43e-05	0.000462	CcSEcCtD
Gliclazide—Asthenia—Docetaxel—ovarian cancer	8.39e-05	0.00046	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—ovarian cancer	8.37e-05	0.000459	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—ovarian cancer	8.34e-05	0.000457	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—ovarian cancer	8.3e-05	0.000455	CcSEcCtD
Gliclazide—Pruritus—Docetaxel—ovarian cancer	8.27e-05	0.000453	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—ovarian cancer	8.27e-05	0.000453	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—ovarian cancer	8.23e-05	0.000451	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—ovarian cancer	8.23e-05	0.000451	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—ovarian cancer	8.23e-05	0.000451	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—ovarian cancer	8.22e-05	0.00045	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—ovarian cancer	8.2e-05	0.000449	CcSEcCtD
Gliclazide—Nausea—Paclitaxel—ovarian cancer	8.2e-05	0.000449	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	8.17e-05	0.000448	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—ovarian cancer	8.13e-05	0.000445	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—ovarian cancer	8.06e-05	0.000442	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—ovarian cancer	8.05e-05	0.000441	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—ovarian cancer	8.01e-05	0.000439	CcSEcCtD
Gliclazide—Diarrhoea—Docetaxel—ovarian cancer	8e-05	0.000438	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—ovarian cancer	7.95e-05	0.000436	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—ovarian cancer	7.9e-05	0.000433	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—ovarian cancer	7.86e-05	0.000431	CcSEcCtD
Gliclazide—Infection—Epirubicin—ovarian cancer	7.84e-05	0.000429	CcSEcCtD
Gliclazide—Cough—Doxorubicin—ovarian cancer	7.8e-05	0.000428	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—ovarian cancer	7.75e-05	0.000425	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—ovarian cancer	7.74e-05	0.000424	CcSEcCtD
Gliclazide—Dizziness—Docetaxel—ovarian cancer	7.73e-05	0.000424	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—ovarian cancer	7.72e-05	0.000423	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—ovarian cancer	7.72e-05	0.000423	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—ovarian cancer	7.7e-05	0.000422	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—ovarian cancer	7.66e-05	0.00042	CcSEcCtD
Gliclazide—Hyperhidrosis—Epirubicin—ovarian cancer	7.63e-05	0.000418	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—ovarian cancer	7.61e-05	0.000417	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—ovarian cancer	7.61e-05	0.000417	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—ovarian cancer	7.61e-05	0.000417	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—ovarian cancer	7.59e-05	0.000416	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	7.56e-05	0.000414	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—ovarian cancer	7.52e-05	0.000412	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—ovarian cancer	7.45e-05	0.000408	CcSEcCtD
Gliclazide—Vomiting—Docetaxel—ovarian cancer	7.44e-05	0.000407	CcSEcCtD
Gliclazide—Rash—Docetaxel—ovarian cancer	7.37e-05	0.000404	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—ovarian cancer	7.37e-05	0.000404	CcSEcCtD
Gliclazide—Dermatitis—Docetaxel—ovarian cancer	7.37e-05	0.000404	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—ovarian cancer	7.36e-05	0.000403	CcSEcCtD
Gliclazide—Headache—Docetaxel—ovarian cancer	7.33e-05	0.000401	CcSEcCtD
Gliclazide—Infection—Doxorubicin—ovarian cancer	7.25e-05	0.000397	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	7.19e-05	0.000394	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—ovarian cancer	7.16e-05	0.000392	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—ovarian cancer	7.15e-05	0.000392	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—ovarian cancer	7.13e-05	0.000391	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—ovarian cancer	7.12e-05	0.00039	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—ovarian cancer	7.09e-05	0.000388	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—ovarian cancer	7.08e-05	0.000388	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—ovarian cancer	7.06e-05	0.000387	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—ovarian cancer	7.03e-05	0.000385	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—ovarian cancer	7.01e-05	0.000384	CcSEcCtD
Gliclazide—Nausea—Docetaxel—ovarian cancer	6.95e-05	0.000381	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—ovarian cancer	6.94e-05	0.00038	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—ovarian cancer	6.82e-05	0.000374	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—ovarian cancer	6.81e-05	0.000373	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—ovarian cancer	6.8e-05	0.000373	CcSEcCtD
Gliclazide—Pain—Epirubicin—ovarian cancer	6.75e-05	0.00037	CcSEcCtD
Gliclazide—Constipation—Epirubicin—ovarian cancer	6.75e-05	0.00037	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	6.65e-05	0.000364	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—ovarian cancer	6.6e-05	0.000362	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—ovarian cancer	6.55e-05	0.000359	CcSEcCtD
Gliclazide—Dyspnoea—Doxorubicin—ovarian cancer	6.51e-05	0.000357	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—ovarian cancer	6.5e-05	0.000356	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—ovarian cancer	6.49e-05	0.000356	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—ovarian cancer	6.45e-05	0.000353	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—ovarian cancer	6.42e-05	0.000352	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	6.38e-05	0.000847	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MET—ovarian cancer	6.36e-05	0.000844	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	6.3e-05	0.000345	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—ovarian cancer	6.29e-05	0.000345	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—ovarian cancer	6.27e-05	0.000343	CcSEcCtD
Gliclazide—Pain—Doxorubicin—ovarian cancer	6.24e-05	0.000342	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—ovarian cancer	6.24e-05	0.000342	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—ovarian cancer	6.24e-05	0.000342	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—ovarian cancer	6.24e-05	0.000342	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—IL6ST—ovarian cancer	6.23e-05	0.000827	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL6—ovarian cancer	6.23e-05	0.000827	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	6.2e-05	0.000824	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ATP7B—ovarian cancer	6.19e-05	0.000822	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	6.13e-05	0.000814	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SOD1—ovarian cancer	6.04e-05	0.000801	CbGpPWpGaD
Gliclazide—Feeling abnormal—Doxorubicin—ovarian cancer	6.01e-05	0.00033	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—PIK3CA—ovarian cancer	6.01e-05	0.000797	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	5.98e-05	0.000794	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.97e-05	0.000327	CcSEcCtD
Gliclazide—ABCC8—Metabolism—YAP1—ovarian cancer	5.91e-05	0.000785	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	5.9e-05	0.000783	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CG—ovarian cancer	5.87e-05	0.00078	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—STAT3—ovarian cancer	5.85e-05	0.000777	CbGpPWpGaD
Gliclazide—Hypersensitivity—Epirubicin—ovarian cancer	5.81e-05	0.000318	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—ovarian cancer	5.8e-05	0.000318	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	5.79e-05	0.000768	CbGpPWpGaD
Gliclazide—Abdominal pain—Doxorubicin—ovarian cancer	5.77e-05	0.000316	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—ovarian cancer	5.77e-05	0.000316	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—YAP1—ovarian cancer	5.73e-05	0.000761	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.73e-05	0.000761	CbGpPWpGaD
Gliclazide—Asthenia—Epirubicin—ovarian cancer	5.66e-05	0.00031	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—MAPK3—ovarian cancer	5.59e-05	0.000742	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MMP9—ovarian cancer	5.59e-05	0.000742	CbGpPWpGaD
Gliclazide—Pruritus—Epirubicin—ovarian cancer	5.58e-05	0.000306	CcSEcCtD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	5.58e-05	0.000741	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—MAPK1—ovarian cancer	5.57e-05	0.00074	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HRAS—ovarian cancer	5.56e-05	0.000738	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFA—ovarian cancer	5.42e-05	0.00072	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—MAPK1—ovarian cancer	5.4e-05	0.000717	CbGpPWpGaD
Gliclazide—Diarrhoea—Epirubicin—ovarian cancer	5.4e-05	0.000296	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—ovarian cancer	5.38e-05	0.000295	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—IL6—ovarian cancer	5.37e-05	0.000714	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	5.32e-05	0.000706	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—MAPK1—ovarian cancer	5.32e-05	0.000706	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP2—ovarian cancer	5.3e-05	0.000704	CbGpPWpGaD
Gliclazide—Asthenia—Doxorubicin—ovarian cancer	5.24e-05	0.000287	CcSEcCtD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.22e-05	0.000694	CbGpPWpGaD
Gliclazide—Dizziness—Epirubicin—ovarian cancer	5.22e-05	0.000286	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—ovarian cancer	5.16e-05	0.000686	CbGpPWpGaD
Gliclazide—Pruritus—Doxorubicin—ovarian cancer	5.16e-05	0.000283	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—PIK3CD—ovarian cancer	5.16e-05	0.000685	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HDAC6—ovarian cancer	5.1e-05	0.000678	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NME2—ovarian cancer	5.05e-05	0.00067	CbGpPWpGaD
Gliclazide—Vomiting—Epirubicin—ovarian cancer	5.02e-05	0.000275	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—ovarian cancer	4.99e-05	0.000274	CcSEcCtD
Gliclazide—Rash—Epirubicin—ovarian cancer	4.97e-05	0.000273	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—ovarian cancer	4.97e-05	0.000272	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—NRAS—ovarian cancer	4.96e-05	0.000658	CbGpPWpGaD
Gliclazide—Headache—Epirubicin—ovarian cancer	4.94e-05	0.000271	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—AKT1—ovarian cancer	4.91e-05	0.000651	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—TUBB3—ovarian cancer	4.89e-05	0.000649	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.89e-05	0.000649	CbGpPWpGaD
Gliclazide—Dizziness—Doxorubicin—ovarian cancer	4.83e-05	0.000264	CcSEcCtD
Gliclazide—ABCC8—Metabolism—FASN—ovarian cancer	4.82e-05	0.00064	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—ovarian cancer	4.78e-05	0.000634	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MAPK3—ovarian cancer	4.75e-05	0.00063	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—SLC5A5—ovarian cancer	4.74e-05	0.000629	CbGpPWpGaD
Gliclazide—Nausea—Epirubicin—ovarian cancer	4.69e-05	0.000257	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—FASN—ovarian cancer	4.67e-05	0.000621	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—ERBB2—ovarian cancer	4.65e-05	0.000617	CbGpPWpGaD
Gliclazide—Vomiting—Doxorubicin—ovarian cancer	4.64e-05	0.000254	CcSEcCtD
Gliclazide—Rash—Doxorubicin—ovarian cancer	4.6e-05	0.000252	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—ovarian cancer	4.6e-05	0.000252	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—SLC5A5—ovarian cancer	4.6e-05	0.00061	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—SLC2A1—ovarian cancer	4.58e-05	0.000608	CbGpPWpGaD
Gliclazide—Headache—Doxorubicin—ovarian cancer	4.57e-05	0.000251	CcSEcCtD
Gliclazide—CYP2C19—Metabolism—NME2—ovarian cancer	4.53e-05	0.000601	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—YAP1—ovarian cancer	4.52e-05	0.0006	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MAPK1—ovarian cancer	4.52e-05	0.000599	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—EGFR—ovarian cancer	4.51e-05	0.000599	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CB—ovarian cancer	4.5e-05	0.000597	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—HRAS—ovarian cancer	4.47e-05	0.000594	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—ovarian cancer	4.47e-05	0.000593	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SLC2A1—ovarian cancer	4.44e-05	0.000589	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—XIAP—ovarian cancer	4.43e-05	0.000588	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP1B1—ovarian cancer	4.39e-05	0.000583	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL6—ovarian cancer	4.37e-05	0.000581	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	4.35e-05	0.000577	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—HRAS—ovarian cancer	4.34e-05	0.000576	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—ovarian cancer	4.34e-05	0.000238	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—SMARCA4—ovarian cancer	4.31e-05	0.000573	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SPARC—ovarian cancer	4.28e-05	0.000569	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.28e-05	0.000568	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—KRAS—ovarian cancer	4.26e-05	0.000566	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP1B1—ovarian cancer	4.26e-05	0.000565	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EREG—ovarian cancer	4.21e-05	0.000559	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2—ovarian cancer	4.13e-05	0.000549	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NME2—ovarian cancer	4.13e-05	0.000548	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL6—ovarian cancer	4.09e-05	0.000543	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CTNNB1—ovarian cancer	4.07e-05	0.00054	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	4.02e-05	0.000534	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—ovarian cancer	3.99e-05	0.000529	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PGR—ovarian cancer	3.94e-05	0.000524	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPP2R1A—ovarian cancer	3.89e-05	0.000517	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.84e-05	0.00051	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPP2R1A—ovarian cancer	3.78e-05	0.000501	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PARP1—ovarian cancer	3.67e-05	0.000487	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—ovarian cancer	3.63e-05	0.000481	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ABCB1—ovarian cancer	3.61e-05	0.00048	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—TYMS—ovarian cancer	3.55e-05	0.000471	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—STAT3—ovarian cancer	3.54e-05	0.000471	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NRAS—ovarian cancer	3.54e-05	0.000469	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	3.53e-05	0.000469	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ABCB1—ovarian cancer	3.51e-05	0.000465	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.5e-05	0.000465	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.49e-05	0.000463	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—ovarian cancer	3.47e-05	0.000461	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—ovarian cancer	3.47e-05	0.000461	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NRAS—ovarian cancer	3.47e-05	0.000461	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—TYMS—ovarian cancer	3.44e-05	0.000457	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK3—ovarian cancer	3.39e-05	0.00045	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK3—ovarian cancer	3.32e-05	0.000441	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.26e-05	0.000433	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYTB—ovarian cancer	3.25e-05	0.000432	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK1—ovarian cancer	3.22e-05	0.000428	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—ovarian cancer	3.22e-05	0.000428	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.18e-05	0.000422	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK1—ovarian cancer	3.16e-05	0.00042	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.15e-05	0.000418	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.13e-05	0.000416	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SOD1—ovarian cancer	3.11e-05	0.000413	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PPP2R1A—ovarian cancer	3.1e-05	0.000411	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	3.08e-05	0.000409	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—ovarian cancer	3.04e-05	0.000404	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—ovarian cancer	2.99e-05	0.000396	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PPP2R1A—ovarian cancer	2.97e-05	0.000395	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYTB—ovarian cancer	2.92e-05	0.000388	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CAV1—ovarian cancer	2.86e-05	0.00038	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.86e-05	0.000379	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.85e-05	0.000379	CbGpPWpGaD
Gliclazide—ALB—Metabolism—BRIP1—ovarian cancer	2.84e-05	0.000377	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPP1CC—ovarian cancer	2.84e-05	0.000377	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—ovarian cancer	2.83e-05	0.000376	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CAV1—ovarian cancer	2.77e-05	0.000368	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—ovarian cancer	2.74e-05	0.000364	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYTB—ovarian cancer	2.66e-05	0.000353	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—ovarian cancer	2.65e-05	0.000352	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CG—ovarian cancer	2.61e-05	0.000346	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.6e-05	0.000345	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—ovarian cancer	2.59e-05	0.000343	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPP1CC—ovarian cancer	2.55e-05	0.000339	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BRIP1—ovarian cancer	2.55e-05	0.000339	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—ovarian cancer	2.54e-05	0.000337	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CG—ovarian cancer	2.53e-05	0.000335	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.49e-05	0.00033	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—ovarian cancer	2.48e-05	0.000329	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	2.4e-05	0.000319	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TERT—ovarian cancer	2.36e-05	0.000314	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BRIP1—ovarian cancer	2.33e-05	0.000309	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPP1CC—ovarian cancer	2.33e-05	0.000309	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CD—ovarian cancer	2.29e-05	0.000304	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—ovarian cancer	2.28e-05	0.000303	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CAV1—ovarian cancer	2.28e-05	0.000302	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	2.27e-05	0.000302	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—ovarian cancer	2.24e-05	0.000297	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CD—ovarian cancer	2.22e-05	0.000295	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CAV1—ovarian cancer	2.19e-05	0.00029	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	2.16e-05	0.000287	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ESR1—ovarian cancer	2.11e-05	0.00028	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CG—ovarian cancer	2.07e-05	0.000275	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6ST—ovarian cancer	2.07e-05	0.000275	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.07e-05	0.000275	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CB—ovarian cancer	2e-05	0.000265	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CG—ovarian cancer	1.99e-05	0.000264	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APC—ovarian cancer	1.99e-05	0.000264	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CB—ovarian cancer	1.94e-05	0.000257	CbGpPWpGaD
Gliclazide—ALB—Metabolism—YAP1—ovarian cancer	1.91e-05	0.000253	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.89e-05	0.00025	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	1.88e-05	0.000249	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.86e-05	0.000247	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CD—ovarian cancer	1.82e-05	0.000242	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CD—ovarian cancer	1.75e-05	0.000232	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—ovarian cancer	1.73e-05	0.000229	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—YAP1—ovarian cancer	1.71e-05	0.000227	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.7e-05	0.000225	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.69e-05	0.000225	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—ovarian cancer	1.67e-05	0.000222	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.66e-05	0.00022	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CB—ovarian cancer	1.59e-05	0.000211	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—YAP1—ovarian cancer	1.56e-05	0.000207	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FASN—ovarian cancer	1.55e-05	0.000206	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—ovarian cancer	1.55e-05	0.000205	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.54e-05	0.000205	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.53e-05	0.000204	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC5A5—ovarian cancer	1.53e-05	0.000203	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MTOR—ovarian cancer	1.53e-05	0.000203	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CB—ovarian cancer	1.53e-05	0.000203	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.49e-05	0.000198	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC2A1—ovarian cancer	1.48e-05	0.000196	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—ovarian cancer	1.47e-05	0.000195	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—ovarian cancer	1.46e-05	0.000194	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.45e-05	0.000192	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1B—ovarian cancer	1.43e-05	0.00019	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1B1—ovarian cancer	1.42e-05	0.000188	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—ovarian cancer	1.4e-05	0.000186	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—ovarian cancer	1.4e-05	0.000186	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FASN—ovarian cancer	1.4e-05	0.000185	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC5A5—ovarian cancer	1.37e-05	0.000182	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—ovarian cancer	1.37e-05	0.000181	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.36e-05	0.00018	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNB1—ovarian cancer	1.35e-05	0.00018	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—ovarian cancer	1.33e-05	0.000176	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC2A1—ovarian cancer	1.33e-05	0.000176	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—ovarian cancer	1.32e-05	0.000175	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.3e-05	0.000172	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FASN—ovarian cancer	1.27e-05	0.000169	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1B1—ovarian cancer	1.27e-05	0.000169	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPP2R1A—ovarian cancer	1.26e-05	0.000167	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.25e-05	0.000166	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.25e-05	0.000166	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—ovarian cancer	1.24e-05	0.000165	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—ovarian cancer	1.22e-05	0.000163	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—ovarian cancer	1.22e-05	0.000162	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.21e-05	0.00016	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.18e-05	0.000157	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—ovarian cancer	1.18e-05	0.000157	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—ovarian cancer	1.18e-05	0.000157	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—ovarian cancer	1.18e-05	0.000156	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK3—ovarian cancer	1.17e-05	0.000156	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCB1—ovarian cancer	1.17e-05	0.000155	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.16e-05	0.000154	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMS—ovarian cancer	1.14e-05	0.000152	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	1.13e-05	0.00015	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK3—ovarian cancer	1.13e-05	0.00015	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.12e-05	0.000149	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK1—ovarian cancer	1.12e-05	0.000148	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—ovarian cancer	1.1e-05	0.000145	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK1—ovarian cancer	1.07e-05	0.000142	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—ovarian cancer	1.07e-05	0.000142	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—ovarian cancer	1.05e-05	0.00014	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCB1—ovarian cancer	1.05e-05	0.000139	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMS—ovarian cancer	1.03e-05	0.000136	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	1.03e-05	0.000136	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.02e-05	0.000136	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—ovarian cancer	1.01e-05	0.000134	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—ovarian cancer	9.94e-06	0.000132	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—ovarian cancer	9.68e-06	0.000129	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—ovarian cancer	9.64e-06	0.000128	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCB1—ovarian cancer	9.54e-06	0.000127	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMS—ovarian cancer	9.37e-06	0.000124	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—ovarian cancer	9.36e-06	0.000124	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—ovarian cancer	9.3e-06	0.000123	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CAV1—ovarian cancer	9.22e-06	0.000122	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—ovarian cancer	9e-06	0.000119	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—ovarian cancer	8.96e-06	0.000119	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.81e-06	0.000117	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—ovarian cancer	8.6e-06	0.000114	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CG—ovarian cancer	8.4e-06	0.000112	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CAV1—ovarian cancer	8.28e-06	0.00011	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—ovarian cancer	8.23e-06	0.000109	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.91e-06	0.000105	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—ovarian cancer	7.91e-06	0.000105	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—ovarian cancer	7.6e-06	0.000101	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CAV1—ovarian cancer	7.55e-06	0.0001	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CG—ovarian cancer	7.54e-06	0.0001	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CD—ovarian cancer	7.39e-06	9.81e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.21e-06	9.58e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CG—ovarian cancer	6.88e-06	9.13e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CD—ovarian cancer	6.63e-06	8.8e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CB—ovarian cancer	6.44e-06	8.55e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CD—ovarian cancer	6.05e-06	8.03e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CB—ovarian cancer	5.78e-06	7.67e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—ovarian cancer	5.56e-06	7.39e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CB—ovarian cancer	5.27e-06	7e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—ovarian cancer	4.99e-06	6.63e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—ovarian cancer	4.55e-06	6.05e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—ovarian cancer	3.92e-06	5.21e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—ovarian cancer	3.52e-06	4.68e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—ovarian cancer	3.21e-06	4.27e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—ovarian cancer	3.21e-06	4.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—ovarian cancer	2.88e-06	3.82e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—ovarian cancer	2.62e-06	3.48e-05	CbGpPWpGaD
